FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377019992> ?p ?o ?g. }

• W4377019992 endingPage "260" @default.
• W4377019992 startingPage "255" @default.
• W4377019992 abstract "Effective vaccines against the SARS-CoV-2 are already available and offer a promising action to control the COVID-19 pandemic. IBD patients on biological agents accept the vaccine as well as an additional dose if recommended. Vaccination against COVID-19 prevents its severe forms and associated mortality and offers a promising action to control this pandemic. In September 2021, an additional dose of vaccine was approved in patients with immunosuppression including IBD patients on biologic agents. We evaluated the vaccination rate and additional dose willingness in this group of at risk patients. A single-center, cross-sectional study was performed among IBD patients on biologic agents and eligible for an additional dose of the COVID-19 vaccine. IBD clinical characteristics and type of vaccine and date of administration were checked in medical records. Acceptance was evaluated after telephone or face-to-face surveys in IBD patients. Out of a total of 344 patients, 269 patients (46.1% male; mean age 47 ± 16 years; Crohn's disease 73.6%) were included. Only 15 (5.6%) patients refused the COVID-19 vaccine mainly (40%) for conviction (COVID-19 pandemic denial). 33.3% would re-consider after discussing with their doctor and/or receiving information on the adverse effects of the vaccine. Previous to the additional dose, the COVID-19 vaccination was present in 94.4% of patients (n = 254). Adverse effects occurred in 53.9% of the cases, mainly pain in the arm (40%). Up to 94.1% of the patients agreed to an additional dose and 79.4% had already received the additional dose at the final time of the assessment. IBD patients on biological agents accept the vaccine as well as an additional dose if recommended. Physicians in charge of IBD units should provide information and confidence in the use of the vaccine in these IBD patients. La vacunación frente al COVID-19 constituye una acción prometedora para controlar esta pandemia. En septiembre de 2021, se aprobó una dosis adicional de vacuna en pacientes con inmunosupresión, incluidos los pacientes con enfermedad inflamatoria intestinal (EII) que reciben agentes biológicos. En este estudio se evaluó la tasa de vacunación y la disposición de recibir la dosis adicional de vacuna en este grupo de pacientes de riesgo. Se realizó un estudio transversal unicéntrico con pacientes afectos de EII con tratamiento biológico y elegibles para una dosis adicional de la vacuna COVID-19. Se evaluó la aceptación y los efectos adversos de la vacuna mediante encuesta telefónica o presencial y se recopiló en las historias clínicas las características de la EII, el tipo de vacuna recibida y la fecha de administración. De un total de 344 pacientes, 269 (46,1% varones; edad media 47 ± 16 años; enfermedad de Crohn n = 198) fueron incluidos. Solo 15 (5,6%) pacientes rechazaron la vacuna frente al COVID-19, el 40% por convicción (negación de la pandemia COVID-19). Antes de la dosis adicional, la vacuna COVID-19 se había administrado en el 94,4% de los pacientes (n = 254). En el 53,9% de los casos presentaron efectos adversos, principalmente dolor en el brazo (40%). Hasta el 94,1% de los pacientes refería la aceptación de una dosis adicional de la vacuna y el 79,1% ya había recibido esta dosis adicional en el momento de la evaluación final. Los pacientes con EII que reciben agentes biológicos aceptan la vacuna frente al COVID-19, así como una dosis adicional si se les recomienda. Los médicos responsables de las unidades de EII deben proporcionar información y confianza en el uso de la vacuna en estos pacientes." @default.
• W4377019992 created "2023-05-19" @default.
• W4377019992 creator A5001318714 @default.
• W4377019992 creator A5007387989 @default.
• W4377019992 creator A5010647071 @default.
• W4377019992 creator A5022669435 @default.
• W4377019992 creator A5033338073 @default.
• W4377019992 creator A5042183731 @default.
• W4377019992 creator A5053236161 @default.
• W4377019992 creator A5059193792 @default.
• W4377019992 creator A5069891176 @default.
• W4377019992 creator A5072570834 @default.
• W4377019992 creator A5088886548 @default.
• W4377019992 date "2023-04-01" @default.
• W4377019992 modified "2023-09-23" @default.
• W4377019992 title "COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire" @default.
• W4377019992 cites W2218153751 @default.
• W4377019992 cites W2911588915 @default.
• W4377019992 cites W3013588707 @default.
• W4377019992 cites W3125034838 @default.
• W4377019992 cites W3125889898 @default.
• W4377019992 cites W3129085410 @default.
• W4377019992 cites W3158750369 @default.
• W4377019992 cites W3172072605 @default.
• W4377019992 cites W3204679289 @default.
• W4377019992 cites W4205352928 @default.
• W4377019992 doi "https://doi.org/10.1016/j.gastre.2022.05.009" @default.
• W4377019992 hasPublicationYear "2023" @default.
• W4377019992 type Work @default.
• W4377019992 citedByCount "0" @default.
• W4377019992 crossrefType "journal-article" @default.
• W4377019992 hasAuthorship W4377019992A5001318714 @default.
• W4377019992 hasAuthorship W4377019992A5007387989 @default.
• W4377019992 hasAuthorship W4377019992A5010647071 @default.
• W4377019992 hasAuthorship W4377019992A5022669435 @default.
• W4377019992 hasAuthorship W4377019992A5033338073 @default.
• W4377019992 hasAuthorship W4377019992A5042183731 @default.
• W4377019992 hasAuthorship W4377019992A5053236161 @default.
• W4377019992 hasAuthorship W4377019992A5059193792 @default.
• W4377019992 hasAuthorship W4377019992A5069891176 @default.
• W4377019992 hasAuthorship W4377019992A5072570834 @default.
• W4377019992 hasAuthorship W4377019992A5088886548 @default.
• W4377019992 hasConcept C126322002 @default.
• W4377019992 hasConcept C197934379 @default.
• W4377019992 hasConcept C203014093 @default.
• W4377019992 hasConcept C22070199 @default.
• W4377019992 hasConcept C2778260677 @default.
• W4377019992 hasConcept C2779134260 @default.
• W4377019992 hasConcept C2780252810 @default.
• W4377019992 hasConcept C3008058167 @default.
• W4377019992 hasConcept C524204448 @default.
• W4377019992 hasConcept C71924100 @default.
• W4377019992 hasConcept C89623803 @default.
• W4377019992 hasConceptScore W4377019992C126322002 @default.
• W4377019992 hasConceptScore W4377019992C197934379 @default.
• W4377019992 hasConceptScore W4377019992C203014093 @default.
• W4377019992 hasConceptScore W4377019992C22070199 @default.
• W4377019992 hasConceptScore W4377019992C2778260677 @default.
• W4377019992 hasConceptScore W4377019992C2779134260 @default.
• W4377019992 hasConceptScore W4377019992C2780252810 @default.
• W4377019992 hasConceptScore W4377019992C3008058167 @default.
• W4377019992 hasConceptScore W4377019992C524204448 @default.
• W4377019992 hasConceptScore W4377019992C71924100 @default.
• W4377019992 hasConceptScore W4377019992C89623803 @default.
• W4377019992 hasIssue "4" @default.
• W4377019992 hasLocation W43770199921 @default.
• W4377019992 hasOpenAccess W4377019992 @default.
• W4377019992 hasPrimaryLocation W43770199921 @default.
• W4377019992 hasRelatedWork W3025855134 @default.
• W4377019992 hasRelatedWork W3026004364 @default.
• W4377019992 hasRelatedWork W3026016661 @default.
• W4377019992 hasRelatedWork W3027084220 @default.
• W4377019992 hasRelatedWork W3031194495 @default.
• W4377019992 hasRelatedWork W3044479395 @default.
• W4377019992 hasRelatedWork W3093842402 @default.
• W4377019992 hasRelatedWork W3119540162 @default.
• W4377019992 hasRelatedWork W3162081874 @default.
• W4377019992 hasRelatedWork W4220930705 @default.
• W4377019992 hasVolume "46" @default.
• W4377019992 isParatext "false" @default.
• W4377019992 isRetracted "false" @default.
• W4377019992 workType "article" @default.